Comparison of Indinavir Sulphate Dosages in HIV-Infected Individuals on Concomitant Therapy With 2 Nucleoside Analogue Reverse Transcriptase Inhibitors
This study aims to compare the effectiveness of different dosages of Indinavir Sulphate in individuals infected with HIV who are also undergoing concomitant therapy with 2 Nucleoside Analogue Reverse Transcriptase Inhibitors.
Indinavir sulfate
Blood-Borne Infections+11
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
In this open-label study 350 seropositive HIV-1 men and women are first stratified according to baseline plasma viral RNA (less than 400 copies/mL vs negative plasma viral RNA result) then randomized into one of two arms: Arm 1: Indinavir (800 mg, q8h) plus two pre-existing NRTIs. Arm 2: Indinavir (1,200 mg, q12h) plus two pre-existing NRTIs. Plasma viral RNA will be measured every 4 weeks for the duration of the 24-week study.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.350 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 16 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 29 locations
Kaiser Permanente / Infectious Disease
Los Angeles, United StatesTower ID Med Associates
Los Angeles, United StatesCtr for AIDS Research / Education and Service (CARES)
Sacramento, United States